Q1 2026 Eli Lilly and Co Earnings Call Transcript
Key Points
- Eli Lilly and Co (LLY) reported a robust revenue growth of 56% compared to Q1 2025, driven by key products like Zepbound and Mounjaro.
- The company achieved several key pipeline milestones, including positive Phase 3 data for multiple products such as Jaypirca and Ebglyss.
- Eli Lilly and Co (LLY) announced multiple business development transactions, including acquisitions of companies with promising clinical stage programs.
- The launch of Foundayo, a new oral GLP-1 therapy for obesity, has shown early positive feedback from payers, physicians, and patients.
- Eli Lilly and Co (LLY) increased its full-year revenue guidance, reflecting strong performance and confidence in future growth.
- Gross margin as a percentage of revenue decreased by approximately 1 percentage point compared to the same quarter last year.
- Marketing, selling, and administrative expenses increased by 19%, reflecting higher investments in promotional activities.
- The US price declined by 7%, with further declines expected due to pricing adjustments and competitive pressures.
- The loss of Medicaid access in certain states negatively impacted Zepbound prescription growth in the high single digits.
- The launch of Foundayo is still in its early stages, with the need for significant efforts to build brand awareness and access.
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2026 earnings conference call. (Operator Instructions) I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2026 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations.
Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Product Officer; Adrienne Brown, President of Lilly Immunology; Dr. Carole Ho, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly USA and Global Customer Capabilities; Jake Van Naarden, President of Lilly Oncology and Head of Business Development; Patrik Jonsson, President of Lilly International; and Ken Kuster, President of Lilly CardioMetabolic Health. We're also joined by the Investor Relations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
